The EGFR signalingpathway is frequently dysregulated in early stage breast cancer andis associated with altered circulating EGFR levels, supporting itsutility as both a circulating biomarker and therapeutic target. Similarly, the AMPK signaling pathway actsas a central regulator of cellular metabolism and immune modulationwithin the tumor microenvironment, positioning it as a promising targetfor cancer therapy. Together, EGFR andAMPK pathways represent biological meaningful targets in breast cancerpathophysiology and are actively pursued in precision oncology. This evidence concerns the gene EGFR and breast carcinoma.